Cite
Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
MLA
Namkaew, Jirapat, et al. “Repositioning of Mifepristone as an Integrated Stress Response Activator to Potentiate Cisplatin Efficacy in Non-Small Cell Lung Cancer.” Cancer Letters, vol. 582, Feb. 2024, p. 216509. EBSCOhost, https://doi.org/10.1016/j.canlet.2023.216509.
APA
Namkaew, J., Zhang, J., Yamakawa, N., Hamada, Y., Tsugawa, K., Oyadomari, M., Miyake, M., Katagiri, T., & Oyadomari, S. (2024). Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer. Cancer Letters, 582, 216509. https://doi.org/10.1016/j.canlet.2023.216509
Chicago
Namkaew, Jirapat, Jun Zhang, Norio Yamakawa, Yoshimasa Hamada, Kazue Tsugawa, Miho Oyadomari, Masato Miyake, Toyomasa Katagiri, and Seiichi Oyadomari. 2024. “Repositioning of Mifepristone as an Integrated Stress Response Activator to Potentiate Cisplatin Efficacy in Non-Small Cell Lung Cancer.” Cancer Letters 582 (February): 216509. doi:10.1016/j.canlet.2023.216509.